Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
SE

Suad Efendic — 12 Patents

Eli Lilly: 6 patents #573 of 2,858Top 25%
NANovo Nordisk A/S: 2 patents #622 of 1,775Top 40%
BABiocrine Ab: 1 patents #4 of 9Top 45%
GTGoverning Council Of The University Of Toronto: 1 patents #286 of 760Top 40%
Mariestad, SE: #2 of 46 inventorsTop 5%
Overall (All Time): #396,045 of 4,157,543Top 10%
12 Patents All Time
Suad Efendic has been granted 12 US patents while listed as an inventor at Eli Lilly. The first was granted in 1997 and the most recent in June 2012. Suad Efendic ranks #396,045 of 4,157,543 US inventors in our database (top 9.5%). Patent records list Suad Efendic in Mariestad, SE.

Issued Patents All Time

Showing 1–12 of 12 patents

Patent #TitleCo-InventorsDateApprox Value ⓘ
8206722 Somatostatin receptor antagonists and glucose control or hypoglycemia Mladen Vranic, Jessica Yue 2012-06-26
7862825 Method of controlling tight blood glucose by somatostatin receptor antagonists Mladen Vranic, Jessica Yue 2011-01-04
7381523 Methods for identifying compounds for treating diabetes mellitus 2008-06-03
7211557 Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity Richard D. DiMarchi 2007-05-01 $177,756,000
6747006 Use of GLP-1 or analogs in treatment of myocardial infarction 2004-06-08 $222,865,000
6583111 Use of GLP-1 analogs and derivative adminstered peripherally in regulation of obesity Richard D. DiMarchi 2003-06-24 $278,101,000
6348447 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein Per Hellstrom 2002-02-19
6277819 Use of GLP-1 or analogs in treatment of myocardial infarction 2001-08-21 $805,041,000
RE37302 Peptide Mark Gutniak, Ole Kirk 2001-07-31
6191102 Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity Richard D. DiMarchi 2001-02-20 $393,022,000
6006753 Use of GLP-1 or analogs to abolish catabolic changes after surgery 1999-12-28 $78,907,000
5631224 Use of a peptide Mark Gutniak, Ole Kirk 1997-05-20 $728,000